ALX Oncology (ALXO) Q4 2025 earnings review
Cash Secured, Burn Stabilized, but Timelines Slip
ALX Oncology enters 2026 in a much stronger financial position than a year ago, successfully pricing a $150M offering in February that extends its runway to 1H 2028. The company's pipeline prioritization strategy has achieved a stable burn rate, with quarterly R&D expenses leveling off around $17.6M after peaking earlier in 2025. However, while management highlights 'strong execution,' a closer look at the data reveals decelerating clinical timelines. Data readouts for both the flagship ASPEN-09 trial and the early-stage ALX2004 program have been quietly pushed back, meaning investors will have to wait significantly longer for the next major catalysts.
🐂 Bull Case
The February 2026 $150M equity raise removes near-term financing overhang. With pro-forma cash of ~$188M and a stabilized quarterly burn rate of ~$23M, the company has runway through 1H 2028.
ASPEN-06 data definitively proves that CD47 overexpression is a predictive biomarker for Evorpacept. A 65% ORR and 18.4-month PFS in CD47-high patients provide a clear, targeted path forward.
🐻 Bear Case
Execution on clinical timelines is decelerating. ALX2004 safety data slipped from 1H to 2H 2026, and the crucial ASPEN-09 breast cancer readout shifted from an interim Q3 2026 target to a topline mid-2027 target.
After abandoning trials in Urothelial and Head & Neck cancers, and pausing Colorectal cancer development, the company's valuation is highly dependent on Evorpacept succeeding in Breast Cancer.
⚖️ Verdict: ⚪
Neutral. Management successfully fixed the balance sheet and stopped the cash bleed. However, the slipping clinical timelines mean the stock lacks near-term catalysts, turning this into a 'show-me' story for late 2026/2027.
Key Themes
CD47 Biomarker Validates Evorpacept's Efficacy
The identification of CD47 overexpression as a predictive biomarker fundamentally transforms Evorpacept's outlook. In the ASPEN-06 gastric cancer trial, patients with retained HER2-positive and CD47-high status saw Objective Response Rates (ORR) hit 65.0% vs 26.1% for the control arm. Crucially, the median Progression-Free Survival (mPFS) was 18.4 months versus just 7.0 months for the control (HR 0.39). This provides a much higher probability of clinical success for the ongoing breast cancer trials.
Clinical Timelines Decelerating
Despite management claiming 'strong 2025 execution,' a review of prior guidance reveals clear timeline slippage that contradicts the positive narrative. In Q3 2025, ALX guided for ALX2004 initial safety data in 1H 2026 and ASPEN-09 interim data in Q3 2026. The Q4 release pushes the ALX2004 readout to 2H 2026 and shifts ASPEN-09 expectations to 'topline data for 80 patients in mid-2027.' This delay leaves a catalyst vacuum for the next 12-18 months.
ALX2004 Progress Validates Internal R&D
The novel EGFR-targeted antibody-drug conjugate (ADC), ALX2004, represents vital pipeline diversification. The Phase 1 dose-escalation trial successfully cleared its first two dose cohorts without dose-limiting toxicities and is now enrolling patients at 4mg/kg. Preclinical models demonstrated no skin toxicity or interstitial lung disease, suggesting a potentially best-in-class safety profile.
Biomarker Strategy Creates Enrollment Friction
While targeting CD47-high patients improves efficacy, it creates logistical challenges. Management announced they are expanding total ASPEN-09 enrollment from 80 to up to 120 patients just to ensure they can evaluate the target of 80 CD47-high patients. This implies a significant portion of screened patients will not qualify, slowing trial progression and highlighting execution risk around patient recruitment.
Other KPIs
Stable. The aggressive pipeline prioritization implemented in early 2025 is paying off. R&D expenses plummeted 25% YoY (from $23.5M in 24Q4) and have stabilized in the $17M-$18M range over the last three quarters. The lower run-rate is primarily driven by reduced clinical material manufacturing and lower stock-based compensation.
Accelerating significantly. The company ended 25Q4 with a dangerously low $48.3M. However, the February 2026 registered offering brought in $140.4M in net proceeds. This completely removes the near-term financing overhang and ensures the company is fully funded through its delayed 2027 clinical milestones.
Decreasing slightly by 8% YoY from $26.1M in FY24. This reflects disciplined cost control on the corporate side, primarily via lower legal fees and stock-based compensation, ensuring maximum capital is directed toward the clinical pipeline.
Guidance
Accelerating vs prior quarter guidance of 'Q1 2027'. The $150M gross equity offering fundamentally changed the company's financial trajectory, providing over two years of additional operating buffer.
Decelerating. This is a noticeable delay from the '1H 2026' guidance provided just one quarter ago in the Q3 2025 materials.
Decelerating. Prior guidance indicated interim data by Q3 2026. The shift to a mid-2027 topline readout indicates slower-than-anticipated enrollment, likely exacerbated by the need to screen for CD47-high status.
Key Questions
Drivers of the ALX2004 Delay
Guidance for ALX2004 initial safety data shifted from 1H 2026 to 2H 2026. Was this delay caused by slower patient enrollment, or did the protocol require longer observation periods between dose cohorts?
ASPEN-09 Enrollment Bottlenecks
You are expanding the ASPEN-09 trial denominator from 80 to 120 patients to hit the target of 80 CD47-high patients. Is the 'screen failure' rate for the CD47 biomarker coming in higher than the ~50% literature estimates you previously cited?
Capital Allocation for Paused Programs
With the cash runway now extended to 1H 2028, are you considering un-pausing the ASPEN-CRC trial, or will the new capital be strictly ring-fenced for Breast Cancer and the ALX2004 scale-up?